Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis

NCT07565103 is registered in ClinicalTrials.gov with Senju USA, Inc. as lead sponsor.

NCT NCT07565103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis
Lead sponsor
Senju USA, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 25, 2026
Completion date
August 15, 2028
Enrollment
426 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial conjunctivitis